All In Biotech

Drug Trial Radar · NCT03100149

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 11-Year All-Participants-on-Treatment Extension

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 316 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

316

Actual

Start

Jun 27, 2017

Primary completion

Nov 27, 2019

Study completion Dec 1, 2031

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Prothena Biosciences Limited
First posted
Apr 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 520 weeks.

Conditions

  • Parkinson's Disease

Interventions

  • RO7046015Drug

    RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.

  • RO7046015Drug

    RO7046015 will be administered at dose of 1512 mg to all participants in the indicated arm.

  • PlaceboDrug

    RO7046015 placebo will be administered to all participants in the indicated arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52Time frame: From baseline to Week 52

Locations

55 sites in 5 countries. Site status is shown where the registry gives one.

  • Uab Medicine

    Birmingham, Alabama

  • Barrow Neurology Clinics

    Phoenix, Arizona

  • Neurology Center of North Orange County

    Fullerton, California

  • USC Keck Medical Center of USC

    Los Angeles, California

  • University of California at San Francisco

    San Francisco, California

  • CenExel Rocky Mountain Clinical Research, LLC

    Englewood, Colorado

  • Associated Neurologists of Southern CT PC

    Fairfield, Connecticut

  • Molecular Neurolmaging

    New Haven, Connecticut

  • Aventura Neurologic Associates

    Aventura, Florida

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • USF Parkinsons Disease and Movement Disorders Center

    Tampa, Florida

  • Northwestern University

    Evanston, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Quest Research Institute

    Farmington Hills, Michigan

  • Corewell Health Neurology and Epilepsy - Beltline

    Grand Rapids, Michigan

  • Henry Ford Health System

    West Bloomfield, Michigan

  • Columbia University

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • The Movement Disorder Clinic of Oklahoma

    Tulsa, Oklahoma

  • Oregon Health & Science Uni

    Portland, Oregon

  • UNIVERSITY of PENNSYLVANIA

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor College

    Houston, Texas

  • Central Texas Neurology Consultants

    Round Rock, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • Groupe Hospitalier Pellegrin

    Bordeaux, France

  • Hopital Gabriel Montpied

    Clermont-Ferrand, France

  • Hopital Henri Mondor

    Créteil, France

  • Hôpital Michallon - Centre d'Investigation Clinique

    Grenoble, France

  • hopital de la Timone

    Marseille, France

  • CHU de Nice Hopital Pasteur

    Nice, France

  • Hopital Pitie-Salpetriere APHP

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • CHU Rouen Charles Nicolle

    Rouen, France

  • CHU de Nantes - Hopital Laennec

    Saint-Herblain, France

  • CIC - Hôpital Purpan

    Toulouse, France

  • Klinik fur Neurologie

    Berlin, Germany

  • Heinrich-Heine Universitätsklinik Düsseldorf

    Düsseldorf, Germany

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.